BioCardia, Inc. (NASDAQ:BCDA) Sees Large Growth in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 86,300 shares, an increase of 72.6% from the October 15th total of 50,000 shares. Based on an average daily trading volume, of 831,300 shares, the short-interest ratio is presently 0.1 days. Approximately 3.2% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Monday, October 28th.

BioCardia Price Performance

Shares of BCDA opened at $2.35 on Thursday. The business’s 50-day moving average is $2.60 and its 200-day moving average is $3.37. The company has a market capitalization of $4.98 million, a price-to-earnings ratio of -0.44 and a beta of 1.28. BioCardia has a fifty-two week low of $1.96 and a fifty-two week high of $23.25.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.78). Equities research analysts expect that BioCardia will post -5.06 earnings per share for the current fiscal year.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.